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Major Concepts 
 
• The presence of non-alcoholic fatty liver disease (NAFLD) in subjects with a BMI within 
the ethnic-specific cut-off of 25 kg/m2 BMI in Caucasian and 23 kg/ m2 in Asian has been 
defined as ‘Lean’ NAFLD. 
• ‘Lean’ NAFLD has been initially described in the Asian population; it can be diagnosed in 
approximately 5%–26% of the general population in Asia and 7-20% in the Western world. 
• Pathophysiological mechanisms are not totally understood and may include a dysfunctional 
adipose tissue, altered body composition, genetic mutations, epigenetic changes occurring 
early in life and a different pattern of gut microbiota.  
• Although this phenotype has generally a more favorable metabolic profile when compared 
to obese NAFLD, ‘Lean’ NAFLD patients can develop the full spectrum of liver damage 
that characterize non-lean NAFLD. 
• Data on long-term prognosis of lean patients are insufficient and controversial but suggest 
that ‘Lean’ NAFLD is not a “benign” disease 
• General recommendations include an adoption of a healthy lifestyle, but guidelines do not 
provide much information as to whether and to what extent prevention and treatment 
should be adapted in lean patients, given the harder correction of underlying risk factors. 
 
 
 
 
 
 
  
Abstract 
Non alcoholic Fatty Liver Disease (NAFLD) is generally associated with obesity and the related co-
morbidities but it can also develop in subjects with a BMI within the ethnic-specific cut-off of 25 
kg/ m2 BMI in Caucasian and 23 kg/ m2 in Asian subjects, the so-called ‘lean’ NAFLD. This sub-
phenotype of NAFLD patients has been described across populations of different ethnicity, 
particularly in Asia, but it can be diagnosed in 10%-20% of non-obese Americans and Caucasians. 
Pathophysiological mechanisms underpinning the “lean” phenotype are not completely understood, 
but they may include a more dysfunctional fat (visceral obesity, differences in adipocyte 
differentiation and altered lipid turnover), altered body composition (decreased muscle mass), a 
genetic background, not limited to PNPLA3 C>G polymorphisms, epigenetic changes occurring 
early in life and a different pattern of gut microbiota. Lean subjects with NAFLD have milder 
features of the metabolic syndrome when compared to obese patients.  Nonetheless they have a 
higher prevalence of metabolic alterations (e.g. dyslipidemia, arterial hypertension, insulin 
resistance and diabetes) compared to healthy controls. Data on histological severity are 
controversial, but they can develop the full spectrum of liver disease associated with Non Alcoholic 
Steatohepatitis (NASH). Since ‘Lean’ NAFLD usually present with less obesity-related 
comorbidities, it is commonly believed that this group would follow a relatively benign clinical 
course but recent data challenge this concept. Here we describe the current knowledge about 
NAFLD in lean individuals and highlight the unanswered questions and gaps in the field.  
 
Introduction 
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most frequent cause of liver 
disease in Western countries, with an almost exponential increase in South America, Asia and in the 
Middle East. From its early description, we know that NAFLD is intimately connected with obesity, 
Type 2 diabetes (T2DM) and the Metabolic Syndrome (MetS), therefore its spread in parallel with 
the worldwide pandemic of obesity is not surprising. Nevertheless, NAFLD can develop in the 
absence of obesity, the so-called ‘lean’ NAFLD (i.e. BMI within the ethnic-specific cut-off of 25 
kg/m2 in Caucasian and 23 kg/m2 in Asian subjects). By this definition, NAFLD in subjects with 
normal BMI has been frequently described in the Asian population, but it can be diagnosed in 10%-
20% of non-obese Americans and Caucasians1,2. Despite the apparent ‘healthier’ phenotype, these 
patients may display the whole spectrum of the histopathological features of Non-alcoholic 
steatohepatitis (NASH), i.e. steatosis, lobular inflammation, hepatocyte ballooning and/or fibrosis3. 
Overall, many clinicians have a perception of ‘lean’ NAFLD being more “benign” in nature, but 
recent data challenge this view and suggest that it should not be overlooked. 
It is conceivable that  ‘lean’ NAFLD comprises an heterogeneous spectrum of different causes 
(Table 1), ranging from environmental cases (such as high fructose and high fat intake) , body fat 
distribution (visceral obesity as opposed to general obesity), body composition (acquired or 
congenital lipodistrophy, sarcopenia)  and genetic risk factors, including rare congenital defects of 
metabolism such as Lysosomal Acid Lipase Deficiency (LAL-D) and Familial Hypobetalipoprotein 
B (FHLB). While the description of secondary causes of ‘lean’ NAFLD is beyond the scope of this 
review, we will describe the current knowledge about NAFLD in lean individuals and highlight the 
unanswered questions and gaps in the field.  
 
Epidemiology  
Epidemiological studies about prevalence, incidence and natural history of NAFLD and NASH in 
lean subjects suffer from several limitations: on one hand, the ‘classic’ bias of the criteria adopted 
to define NAFLD in the general population (liver function tests vs imaging vs algorythms) and the 
lack of non-invasive markers for NASH; on the other the heterogeneous definition of ‘lean’ across 
studies. In fact, while most of these studies compared patients using 25 as BMI cut-off, in Asian 
cohorts the term ‘lean’ should be used according to the ethnic-specific BMI cut-off of 23, while 
patients with BMI < 25 should be commonly indicated as “non-obese”4. In this regard, interpreting 
BMI values with the simplistic association between low BMI and low body fat is misleading 
because BMI is an imperfect index of adiposity, particularly in truncal fat accumulation, and does 
not take into account body composition. Adding to the confusion is that the definition of MetS, 
commonly used to detect metabolic abnormalities, varies across studies and even more at the 
individual level, so that the association between the degree of obesity and development of insulin 
resistance may not be so clear-cut.   
Population studies had being describing NAFLD in non-obese subjects since 2006 (Table 2). In a 
study including 2520 residents of the Shengang Township in Taiwan, NAFLD (by abdominal 
ultrasound) was found in 61 over 1,444 non-obese participants (4.2%), in the absence of other 
etiologies of chronic liver disease5. In a prospective epidemiological study carried in a very poor, 
rural area of West Bengal, India, NAFLD was identified in 8.6% of the overall population, but 75% 
of NAFLD subjects belonged to the non-obese group6. The non-obese and lean individuals with 
NAFLD had more subcutaneous fat, higher fasting blood glucose, and higher levels of triglycerides. 
However this population also included 47% with malnutrition, which can be associated with 
NAFLD by a different mechanism (choline deficiency). 
After these two pioneer epidemiological surveys, most of the studies investigating the non-obese 
pattern of NAFLD had been carried out in the Asian continent. In China, the Zhejiang Zhenhai 
Study evaluated the prevalence and risk factors of NAFLD in 6,905 non-obese individuals (BMI < 
25). NAFLD was diagnosed by ultrasound in 7.27% of the study participants7. Similarly, in a cohort 
of 2,000 Chinese subjects who received annual physical examinations, NAFLD was found in nearly 
18% of the non-obese subjects (BMI < 24)8. A large Korean population study recruiting 29,994 
individuals who presented for a routine health evaluation, reported a prevalence of NAFLD of 
12.6% in the non-obese participants (n=3,014)9. These findings were confirmed in another Korean 
general medical check-up program where 22.4%, of non-obese subjects (333/1,487) had NAFLD10. 
In Japan, the overall prevalence of NAFLD in 3,271 subjects who received health checkups from 
2011 to 2012 was 68.5% in obese subjects and 15.2% in non-obese subjects. Metabolic factors such 
as waist circumference and triglycerides were predictors of non-obese NAFLD. Interestingly, 
weight gain since early adulthood (around the age of 20) was significantly associated with NAFLD 
in non-obese subjects of both genders11. In a community-based Hong-Kong cohort NAFLD was 
detected by Proton-Magnetic Resonance Spectroscopy (1H-MRS) in 19.3% of the lean cases (BMI 
< 23 kg/m2), compared with 61% in those with a higher BMI12.  
Compared to the Asian surveys described above, studies in the Caucasian population are less 
numerous and, in general, involved a smaller number of subjects. In Italy, the Dionysus Study 
showed that the prevalence of ‘lean’ NAFLD (BMI < 25 kg/ m2) assessed by ultrasonography was 
16%, compared with 75.8% in obese13. In Iceland, the AGES-Reykjavik Study Investigators 
highlighted an association between the central axes of obesity with the presence of MetS in lean 
patients14. In this study, CT scan showed the presence of hepatic steatosis even in patients with a 
median BMI of 22.7. In the Dallas Heart Study, the prevalence of steatosis (defined as a hepatic 
triglyceride content > 5.5% by 1H-MRS) in subjects with a BMI < 30 kg/ m2 was 17%, compared 
with 34% in the overall study subjects15. The prevalence of NAFLD was significantly lower in non-
obese African Americans (11%) but comparable in non-obese Caucasians and non-obese Hispanics 
(20% vs 26%; P = .12)15. However, the largest epidemiological study analyzing prevalence and 
features of lean Caucasian NAFLD patients has been carried in the United States, using data of the 
Third National Health and Nutrition Examination Survey III (NHANES III)16. Among 11,613 
subjects, the prevalence of NAFLD at ultrasonography was as high as 27.7% in overweight/obese 
subjects, significantly higher than the 7.4% observed in subjects with normal BMI (<25 kg/ m2).  
The presence of a lean phenotype with NAFLD is observed across all age groups, including 
adolescents. Cross sectional data from 1482 lean subjects (body mass index <85th percentile) aged 
between 12 and 18 years, enrolled in the NHANES during the 2005 to 2014 cycles, reported a 8% 
prevalence of suspected NAFLD (by ALT above the low gender-specific cut-off) among lean 
adolescents. Low HDL, hypertriglyceridemia and presence of insulin resistance were more common 
among ‘Lean’ NAFLD compared with their non-NAFLD counterparts17.  
Overall, epidemiologic data suggest that the prevalence of ‘lean’ NAFLD is approximately 5%–
26% in the Asian population and 7-20% in the Western one. This suggests that factors independent 
from body weight may be important in a subset of NAFLD subjects. 
 
Pathophysiology of Lean NAFLD  
 
Pathologic pathways underlying the development of NAFLD in lean subjects are not entirely 
understood. However, studies on adipose tissue functions, genetic analyses, studies in vitro and in 
vivo on animal models and finally gut microbiome research can provide some hints to mechanisms 
(Figure 1). 
Insulin resistance and fat distribution  
Despite a reduced likelihood of being associated with the components of MetS, subjects with ‘lean’ 
NAFLD are nonetheless insulin resistant when compared to healthy controls. In a cohort of subjects 
with biopsy-proven NAFLD, free of diabetes, obesity and MetS, the metabolic pattern of insulin 
resistance in the main target tissues (muscle, liver and adipose tissue) was similar to that observed 
in obesity, with adipose tissue insulin resistance playing an important role despite a low BMI and 
normal subcutaneous fat18. This early finding was further supported by more recent studies, 
showing higher circulating concentration of free fatty acids (FFA) in ‘lean’ NAFLD patients 
compared to healthy controls and a higher portal FFA flow, which may induce intra-hepatic fat 
accumulation19,20. 
It is likely that a vast part of ‘lean’ NAFLD belong to the phenotype of “metabolically obese normal 
weight” (MONW) subjects, described in at least 5% of the occidental population, who display 
altered insulin sensitivity and increased cardiovascular risk21. When comparing metabolically 
healthy and unhealthy normal weight subjects, the latter population has increased liver fat content, 
visceral fat mass and carotid Intima Media Thickness (cIMT), but lower subcutaneous fat mass, 
insulin sensitivity and insulin secretion22. These key characteristic of MONW are consistent across 
studies in humans; increased liver fat is probably due to a decreased capacity for storing fat in 
subcutaneous adipose tissue, coupled with reduced mitochondrial function and increased de novo 
lipogenesis in the liver22. Further, MONW subjects also have a pro-inflammatory circulating milieu 
characterized by decreased adiponectin concentration and a unique T-cell signature21. Ethnicity has 
a significant impact on the variability of MONW across studies. In the Multi-Ethnic Study of 
Atherosclerosis, the prevalence of metabolically unhealthy with normal weight ranged from 21 % in 
whites, 32 % in Chinese Americans, 31 % in African Americans, 38.5% in Hispanics, and 43.6% in 
South Asians23. In the same study, the prevalence of non-obese NAFLD (BMI < 30 kg/ m2) 
assessed by CT scan was 11%, including 9% among Caucasians, 6% among African Americans, 
and 18% among Hispanic Americans23. 
At the extreme end of the spectrum of MONW lays the lipodystrophy phenotype. These subjects 
typically display absence of fat in the classic subcutaneous depots but large ectopic accumulation of 
lipids in the skeletal muscle and in the liver associated with severe insulin resistance24. While the 
genetic forms are relatively rare, acquired lipodystrophy can be found in HIV patients under 
HAART therapy and can be also found in some lean people not having been diagnosed with 
lipodystrophy.  
The importance of body composition in the onset and progression of NAFLD is also supported by 
the finding that sarcopenia, defined as a progressive and generalized loss of skeletal muscle mass, 
strength and function, is a novel risk factor for the development of NAFLD25. Recently we found 
elevated plasma aminoacids concentrations in NAFLD subjects either with and without obesity, 
likely to be related to peripheral resistance and resulting in increased muscle proteolysis during the 
fasting state, which lends support to the pathogenesis of sarcopenia in NAFLD26. 
 
Genetic and environmental factors  
The data discussed above suggest that ‘lean’ NAFLD have an increased susceptibility to develop 
NAFLD that can be partially attributed to genetic factors or epigenetic changes induced early in life.  
The search for genetic causes that contribute to the incidence of NAFLD in lean patients is still in 
its infancy. As reported by genome-wide association analyses, firstly performed within the Dallas 
Heart Study and widely confirmed in literature, a single variant in the patatin-like phospholipase 
domain-containing protein 3 (PNPLA3), the rs738409[G], encoding I148M, is associated with an 
increase in both liver fat and hepatic inflammation27. Comparing obese and non-obese subjects with 
NAFLD, the prevalence of the PNPLA3 [G] allele was significantly higher among non-obese 
individuals (78.4% vs 59.8%) and was independently associated with NAFLD even in the 
multivariate analysis12. A study recruiting lean Japanese NAFLD patients (BMI < 23) confirmed the 
previous findings. Although there were no GG homozygous carriers in their population, in the lean 
group the G allele was a predictor of NAFLD in all multivariate analysis steps, while it was not in 
the obese population28.  Another Japanese study recruiting 540 biopsy-proven NAFLD patients (134 
non-obese) found a higher rs738409 GG homozygous genotype rate in non-obese NAFLD patients 
compared to obese individuals with fatty liver. Again, the GG-single-nucleotide polymorphism was 
an independent predictor of NAFLD, together with diabetes, in the non-obese cohort only29. In a 
retrospective study on patients with ‘Lean’ NAFLD, the only variable associated independently 
with NASH and a fibrosis score of 2 or higher was rs738409 C>G in PNPLA330. However, in a 
prospective general population study in Hong Kong including 565 cases (BMI < 23 in 72%)  
without evidence of NAFLD (by 1H-NMR) at baseline, the presence of the common variant in the 
PNPLA3 gene did not provide any relevant clue for incident NAFLD31.  
Other variants in different loci may be involved in individual cases. Cholesteryl ester transfer 
protein (CETP) is involved in triglyceride exchange between lipoproteins32. Two single-nucleotide 
polymorphisms (rs12447924 and rs12597002) were associated with fatty liver disease in adolescent 
lean Caucasian females (BMI < 25). The highest risk of NAFLD was found in the group with the 
lowest adiposity assessed by skinfold thickness, where the prevalence of NAFLD in lean 
homozygotes, heterozygotes and wild type was over 30%, 10-15% and 3.5% respectively33.  A 
single-nucleotide polymorphism in transmembrane 6 superfamily member 2 (TM6SF2) was 
associated with NAFLD and fibrosis independent of age, diabetes, obesity and the PNPLA3 
genotype34.  In a retrospective cohort, a significantly greater proportion of patients with ‘Lean’ 
NAFLD carried rs58542926 C>T in TM6SF2 (4%) than obese or overweight individuals30. The 
interferon (IFN) lambda 4 rs368234815 TT>δG variant, influencing innate immunity regulation, 
has been linked to liver damage in patients with NAFLD. The impact of rs368234815 seems 
generally more marked in non-obese individuals, where an association with severe fibrosis, 
necroinflammation, and NASH has been observed35.  
Finally, a recent study on animal models hypothesized that a deficiency of the 
phosphatidylethanolamine N-methyltransferase (PEMT) could play a key role in the development 
of NASH in lean individuals36. PEMT is an enzyme involved in the synthesis of 
phosphatidylcholines in liver cells. PEMT -/- mice on high fat-high sucrose diet did not develop 
obesity or insulin resistance compared to the PEMT +/+ and presented normal cholesterol and 
triglyceride levels. Nonetheless, PEMT -/- developed NASH and after 90 weeks all PEMT -/- mice 
developed liver tumors. When PEMT mRNA expression in human liver biopsies were quantified, a 
lower expression of PEMT was found in patients with NASH. A correlation with lower BMI has 
been also reported, suggesting that PEMT deficiency could be an etiologic agent of lean NASH36.  
Insulin resistance in adipose tissue develops early during fetal growth restriction and is maintained 
during the neonatal period and adulthood37. Besides genetic factors, intrauterine growth might play 
a role in favoring NAFLD, particularly in children. An Italian group first described the association 
of intrauterine growth retardation with pediatric NAFLD and more severe disease activity at 
histology, independent of and in addition to insulin resistance. At an average age of 11 years, most 
study's subjects (80%) were insulin resistant, despite normal BMI and a very low prevalence of 
metabolic abnormalities. Notably, the family history of type 2 diabetes was less common, 
suggesting that genetic factors have lower relevance in the onset of NAFLD in this cohort38. 
The setting of a smaller adipocyte number during early life let lean population mostly change their 
adipocyte volume in adulthood, developing MetS features at a lower fat mass39, partially explaining 
why these subjects easily develop NAFLD for small increases in body weight, still in the non-obese 
range31.  
Finally, among the most common environmental causes, a high fructose intake is an additional risk 
factors for NAFLD and NASH, particularly in children and adolescents. In a study on young non-
obese subjects without obvious metabolic risk factors, the only independent predictor for the 
presence of NAFLD was a higher soft drink and juices consumption, up to 4-fold compared to 
healthy controls40. Thus, preventing fructose intake may represent a readily modifiable 
environmental factor, particularly in younger ‘lean’ NAFLD patients. 
 
Gut Microbiome and Metabolomics  
Fatty liver has been associated with a lower rate of Bacteroidetes and a higher rate of Prevotella 
and Porphyromonas, as well as a higher number of ethanol-producing bacteria41. Duarte et al. 
described a significant difference in the abundance of Faecalibacterium, Ruminococcus, 
Lactobacillus and Bifidobacterium in patients with NASH when compared to controls44. The 
subgroup of lean patients with NASH had had less abundance of Ruminococcus and a deficiency of 
Lactobacilli when compared to overweight and obese patients with NASH42.  
Lyso-phosphatidylcholines (lyso-PCs) are phospholipids with anti-inflammatory and insulin-
sensitizer effects and lower levels of lyso-PCs are observed in obesity43-45. Metabolomic analyses 
demonstrated lower levels of lyso-PCs in both lean and obese NAFLD patients when compared to 
healthy controls46. On the other hand, when compared their obese counterpart, lean patients with 
NAFLD showed a higher level of lysine concentration46. Being related to visceral fat 
accumulation47, lysine may represent a sign of the dysfunctional metabolic environment 
underpinning ‘Lean’ NAFLD individuals.  
 
Clinical and Pathological Features 
Compared to their healthy counterpart, ‘lean’ NAFLD have a reduced likelihood of being associated 
with the components of MetS; nonetheless subjects have an increased prevalence of metabolic 
derangements, above all diabetes  and higher plasma triglycerides, although both abnormalities are 
usually less severe than in obese NAFLD patients16,48. In the NHANES III population, when 
compared with overweight/obese NAFLD subjects, ‘lean’ NAFLD was independently associated 
with younger age, female sex, insulin resistance and hypercholesterolemia. Among individuals who 
fulfilled the clinical definition of NASH as it was adapted for that cohort (i.e. NAFLD patients with 
elevated aminotransferases in the presence of either diabetes or insulin resistance), the prevalence of 
lean subjects was as low as 1.38%16. Another study in Caucasians confirmed that patients with 
‘lean’ NAFLD have a better metabolic profile than overweight and obese, i.e. higher levels of high-
density lipoprotein cholesterol (HDL-C), lower triglyceride and fasting glucose levels, in addition to 
a lower concentration of the pro-inflammatory cytokines IL6 and TNF-α. In addition, leptin levels 
were similar to healthy controls and significantly lower than in obese NAFLD patients. Conversely, 
in ‘lean’ NAFLD adiponectin levels have been found significantly lower than healthy controls, but 
similar to the obese NAFLD46. In Asian cohorts, features of MetS have been associated with the 
development of NAFLD  across the entire BMI spectrum, but lean NAFLD patients presented the 
strongest correlations7,8. Further, ‘Lean’ NAFLD seems to have a more active visceral adipose 
tissue, in terms of visceral adiposity index (an indicator of visceral fat function associated with 
cardiometabolic risk), when compared to overweight or obese population8,49. Noteworthy, in some 
lean healthy subjects relatively small changes in their metabolic profile and body weight can be 
associated with incident ‘lean’ NAFLD. A prospective cohort study from Hong Kong included a 
subgroup of 406 lean (BMI < 23.0 kg/m2) subjects, of whom 7.9% developed incident steatosis (by 
1H-MRS) after an interval of 3–5 years (median 47 months)31. At multivariable analysis, increased 
waist circumference and serum triglyceride levels during follow-up were associated with incident 
fatty liver, although some of these patients did not develop a full MetS.  
Even though a better metabolic profile is supposed to be associated with a less severe histological 
damage, there is no agreement on this issue and some studies suggest the contrary in ‘lean’ 
NAFLD. A seminal Italian study50 reported the presence of NASH in 50% of lean NAFLD patients 
(BMI <25 kg/ m2). The prevalence of NASH was quite similar across BMI classes (normal weight, 
65%; overweight, 73%; and obese, 84%; P = 0.184). Another study including 430 biopsy proven 
NAFLD, showed that 55% of patients without visceral obesity according to waist circumference 
had NASH and fibrosis ≥ F2, despite milder metabolic alterations51. On the contrary, in another 
retrospective series including 669 biopsy-proven Caucasian NAFLD patients, when compared to 
overweight and obese patients, NAFLD subjects with a BMI < 25 had a lower rate of MetS and 
diabetes, lower cardiovascular damage, expressed as cIMT and prevalence of carotid plaques as 
well as lower prevalence of histologically-diagnosed NASH and fibrosis F2 or higher30. Of interest, 
in a Turkish cohort of 483 biopsy-proven NAFLD patients, with a prevalence of ‘Lean’ NAFLD 
(BMI < 25) of 7.6%, high hemoglobin levels was the only independent predictor of NASH and 
advanced fibrosis in lean individuals and not in the obese/overweight group52.  
In a study from China, similar proportions of obese and non-obese patients had NASH (51.9% 
versus 43.5%, P = 0.217), although the latter ones had a lower degree of steatosis and hepatocyte 
ballooning, and the proportion of patients with advanced fibrosis was not different in the two 
groups3. Triglyceride levels independently predicted disease severity in non-obese NAFLD group 
and were associated with both higher grade of steatosis and hepatocyte ballooning3. Similarly, 
Kumar et al. found no difference in NASH prevalence between lean (BMI < 23) and non-lean 
subjects among 110 biopsy-proven NAFLD patients of Indian ethnicity53.  In a Japanese cohort of 
biopsy-proven NAFLD patients, lobular inflammation, hepatocyte ballooning and NAFLD activity 
score were strictly associated with the GG-PNPLA3 single-nucleotide polymorphism, which was 
more prevalent in the non-obese cohort and was not associated with histological severity in NAFLD 
obese patients29.   
Thus, lean NAFLD patients may present milder histological features or may show the same 
characteristics when compared to obese patients with NAFLD, but overall they can display the full 
spectrum of liver damage. This suggests that the risk of cirrhosis for lean NAFLD patients may not 
be that different after all, and that, once NASH is established, obesity may not be the main driver of 
fibrosis progression. The next important question is whether ‘lean’ NAFLD subjects have an 
adverse outcome related to liver-related morbidity and mortality. 
 
Outcome and Prognosis of Lean NAFLD patients 
Since ‘Lean’ NAFLD usually present with less obesity-related comorbidities, it is commonly 
believed that this group would follow a relatively benign clinical course. Within the cohort of the 
NHANES III54, mortality of metabolically-normal NAFLD patients was similar to the cohort 
without liver disease. However, the longitudinal risk of mortality in ‘Lean’ NAFLD has been 
scarcely explored. In the Hong Kong cohort of Leung et al., where 307 patients with biopsy-proven 
NAFLD (23.5% non-obese, BMI < 25) had been followed up for a median period of 49 months, 
clinical events similarly occurred in obese (11.9%) and of non-obese patients (8.3%). 
Cardiovascular morbidity accounted for about two thirds of all major events in both groups. All 
deaths (n=6) occurred in the obese group, but definite conclusions are difficult to make as follow-up 
was relatively short3. An international study with a longer follow-up period, published so far only in 
abstract form, challenged the concept that the prognosis of patients with NAFLD who have normal 
BMI is better than in those who are overweight or obese55. Over a total 1090 prospectively  
recruited  patients, 125  (11.5%) were classified as lean (BMI < 25 for non-Asians and < 23 for 
Asians). ‘Lean’ NAFLD were more commonly men of non-Caucasian origin and, as expected, 
showed less features of the MetS. Histologically, they had less severe fibrosis but a higher grade of 
lobular inflammation. Interestingly, median survival free of liver transplantation was significantly 
shorter in lean than in non-lean patients (18.1 vs. 26.6 years, respectively, p<0.001). The higher risk 
of death/liver transplantation in ‘Lean’ NAFLD was independent of the classic risk factors that may 
influence the development of this outcome.  
In another retrospective study including 646 patients with biopsy‐proven NAFLD, at enrolment 
NAFLD 19% of patients were lean, 52% overweight and 29% obese. Patients with ‘Lean’ NAFLD 
were older, had lower transaminases, lower stages of fibrosis, and lower prevalence of NASH 
compared to patients with a higher BMI. During a mean follow‐up of 19.9 years (range 0.4‐40 
years) patients with ‘Lean’ NAFLD had no increased risk for overall mortality, but they were more 
likely to develop severe liver disease than patients with NAFLD who were overweight (hazard ratio 
2.69; P =  0.007), independent of available confounders56. Three prognostic indicators for mortality 
in ‘Lean’ NAFLD were identified: older age, fibrosis stage, and hypertension.  Noteworthy, of the 
19 patients with ‘Lean’ NAFLD who developed severe liver disease, 58% (n = 11) had fibrosis 
stage 0‐2 at baseline. A limitation of the longitudinal retrospective studies is the limited ability to 
determine whether or not subjects developed additional risk factors over time that are known to 
predispose to advanced liver disease, such as diabetes or changes in alcohol intake and body weight.   
Certainly future longitudinal prospective studies are needed to define the prognosis in ‘Lean’ 
NAFLD and to elucidate potential pathophysiologic mechanisms underlying progression; 
nevertheless data available suggest that carefully selected patients with ‘Lean’ NAFLD likely 
require long‐term follow‐up and reassessment of progression of liver disease over time.  
 Management 
When it comes to the prevention and treatment of ‘Lean’ NAFLD, current European guideline 
states that follow up is mandatory in obesity, but also suggest follow up in lean persons with 
NAFLD because of possible disease progression, even though they have less severe metabolic 
disturbance (B2 strength of evidence)57 . Careful identification and correction of environmental 
causes, such as significant fructose consumption, may be effective particularly in young patients. 
General recommendations include an adoption of a healthy lifestyle and the initiation of 
pharmacological treatments for elevated blood pressure, dyslipidemia, and hyperglycemia, if 
necessary57. However, these guidelines do not provide much information as to whether and to what 
extent prevention and treatment should be adapted in lean patients, given the harder correction of 
underlying risk factors. Weight loss remains the background therapy in all cases with 
overweight/obesity, but in ‘Lean’ NAFLD the efficacy of calorie restriction has not been tested. 
Nevertheless, diet should be prescribed when a weight gain even within the non-obese BMI range 
was preceding the development of ‘Lean’ NAFLD. Importantly, habitual physical activity should 
certainly be indicated because it can specifically decrease visceral fat58. Treatment with the TZD 
pioglitazone also reduced the diabetes risk and improved insulin secretion in non-obese subjects 
with impaired glucose tolerance59, but no analysis had been performed in normal weight 
individuals. Incretin-based treatments may be more effective in overweight and obese subjects than 
in normal weight individuals because its efficacy is associated with weight loss60. In the Liraglutide 
and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) study, which included 9,340 patients, 
treatment with liraglutide was associated with lower incidence of the primary composite outcome in 
obese patients with type 2 diabetes, but not in non-obese61.  
 
Conclusions 
Lean patients with non-alcoholic fatty liver disease are a well-defined entity and are described by 
numerous studies both in the Eastern continent and in the Western world. Considering that lean 
NAFLD patients can develop the full spectrum of liver damage that characterize non-lean NAFLD, 
it is important to understand what phenotypes characterize this population. Compared to healthy 
individuals, lean subjects with NAFLD present metabolic risk factors (dyslipidemia, arterial 
hypertension, diabetes, insulin resistance) to a significantly greater extent, probably due to a more 
dysfunctional adipose tissue, not limited to its visceral component. Although literature data indicate 
that these patients have more favorable metabolic characteristics when compared to obese NAFLD 
patients, data on long-term survival and mortality are insufficient and controversial. Furthermore, 
genetic analyses suggest that metabolic risk appears to be determined by different pathways in 
normal weight and obese subjects and indicates that the genetic background could be the key to 
better characterize this type of patients. These findings may have several implications for clinical 
interventions and for drug development. Applying well-defined phenotyping strategies in clinical 
trials to separate the outcome in lean and obese NAFLD subjects will help to more precisely 
understand the pathophysiology of liver disease. Without a doubt, the challenges that the ‘Lean’ 
NAFLD raises are an excellent incentive for the development of future research. 
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Tables 
Table 1 Possible causes of NAFLD in lean subjects 
High fructose intake 
Metabolically Obese Normal Weight Subjects 
Congenital and acquired  (highly active antiretroviral therapy for HIV) lipodistrophy 
Malnutrition (Kwashiorkor) 
Genetic  
PNPLA 3 GG variant 
Congenital defects of metabolism  
− Familial Hypo-BetaLipoproteinaemia (FHBL) 
− Lysosomal Acid Lipase Deficiency (LAL-D) 
Endocrine disorders (polycystic ovary syndrome, hypothyroidism or growth hormone 
deficiency) 
Drug-related (amiodarone, methotrexate, tamoxifen) 
Jejunoileal bypass, starvation, Total Parenteral Nutrition 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Main epidemiological, cross-sectional and longitudinal studies describing the 
characteristics of “lean” patients in NAFLD 
 
Epidemiological Studies 
 Main findings* Ethnicity 
Chen et al.5, 2006 2520 Taiwanese subjects included. NAFLD was found in 4.2% of non-obese participants. Asian 
Das K et al.6, 2010  Of the 1911 individuals included, NAFLD was found in 8.6% of the population, of whom 
75% were non-obese. 
Indian 
Kwon et al.9, 2012 Large Korean population study (n=29944). NAFLD reported a prevalence of 12.6% in the 
non-obese participants.  
Asian 
Kim et al.14, 2011 Icelandic study including 2945 patients. Hepatic steatosis was shown even in patients with 
a median BMI of 22.7 
Caucasian 
Browning et al.15, 2004 In the Dallas Heart Study cohort, the prevalence of steatosis in subjects with BMI <  30 
was 17% 
Caucasian 
Younossi et al.16, 2012 Among the 11613 subjects of the NHANES III cohort, the prevalence of NAFLD in lean 
individuals was 7.4% 
Caucasian 
Cross-sectional Studies 
C.Selvakumar17, 2018 Among 1482 US lean adolescence, 8% had NAFLD, and had a higher prevalence of low 
HDL, hypertriglyceridemia and insulin resistance.  
Caucasian 
Younossi et al.16, 2012 ‘Lean’ NAFLD was associated with younger age, female sex, insulin resistance and 
hypercholesterolemia  
Caucasian 
Feldman et al.46, 2017 Although lean NAFLD patients have a better metabolic profile, they have lower 
adiponectin levels when compared to healthy controls. 
Caucasian 
Feng et al.8, 2014 ‘Lean’ NAFLD have a more active and pro-inflammatory visceral adipose tissue Asian 
Wong et al.31, 2015 Waist circumference and triglyceride levels predicted the incidence of steatosis in lean 
individuals  
Asian 
Fracanzani et al.30, 2017 Lean patients had a lower rate of MetS, diabetes, lower cardiovascular damage and lower 
hepatic histological damage 
Caucasian 
Akyuz et al.52, 2015 Turkish cohort with lean prevalence of 7.6%. High hemoglobin levels were the only 
independent predictor of NASH and fibrosis in lean subjects. 
Caucasian 
Longitudinal Studies 
Leung et al.3, 2017 Median follow up of 49-months. Hypertriglyceridemia and higher creatinine were 
associated with advanced liver disease in lean. Death and HCC were recorded only in the 
obese group.  
Asian 
Cruz et al.55, 2014  Despite a better metabolic profile, less insulin resistance and fibrosis, lean subjects have a 
higher overall mortality than patients with NAFLD who are overweight or obese. 
Mixed 
Hagstrom et al.56, 2018 After a median follow-up of 19.9 years, although patients with lean NAFLD showed lower 
fibrosis, they were at higher risk for development of severe liver disease compared to 
patients with NAFLD and a higher BMI, independent of available confounders. 
Caucasian 
 
*in all studies, alternative etiologies of liver disease has been excluded. 
BMI: Body Mass Index; NHANES: Third National Health and Nutrition Examination Surve; US: United States; HDL: high-density 
lipoprotein; HCC: hepatocellular carcinoma.  
Figure 1 Pathophysiological Determinants of Non Alcoholic Fatty Liver Disease in Lean 
subjects 
 
AT: Adipose Tissue; FFA: Free Fatty Acids; PNPLA3: patatin-like phospholipase domain-
containing protein 3; TM6SF2: Transmembrane 6 Superfamily Member 2; CETP: Cholesteryl Ester 
Transfer Protein; IFN: Interferon; PEMT: phosphatidylethanolamine N-methyltransferase. 
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